Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%

Inclusion Criteria for Recipient: * End-stage renal disease * No known contraindications for therapy with IGIV-C, 10% * Have identified a living kidney donor * Positive crossmatch with the intended donor * Parent or guardian willing to provide consent, if applicable Exclusion Criteria for Recipient: * Pregnant or breastfeeding * Women of child-bearing age who are not willing or able to practice approved methods of contraception * HIV infection * Hepatitis B or hepatitis C infection * History of positive tuberculin skin test * Selective IgA deficiency, known anti-IgA antibodies, or history of severe allergy to any part of the clinical trial material * Have received or will receive multiple organ transplants * Any licensed or investigational live attenuated vaccine within 2 months of the screening visit * Patients deemed unable to comply with the protocol * Heart attack within 1 year of screening * History of clinically significant thrombotic episodes or active peripheral vascular disease * Investigational agents within 4 weeks of study entry Inclusion Criteria for Donor: * Positive donor-specific crossmatch with the intended recipient * ECOG performance status 0 or 1 * Excellent health * Acceptable laboratory parameters * Compatible blood type * Normal heart and lung evaluations * Parent or guardian willing to provide consent, if applicable